Regardless of personal opinions about his style, Marcus has been proven correct on several fronts, including the diminishing returns of scaling laws and the lack of true reasoning (out of distribution generalizability) in LLM-type AI.

These are issues that the industry initially denied, only to (years) later acknowledge them as their "own recent discoveries" as soon as they had something new to sell (chain-of-thought approach, RL-based LLM, tbc.).

The offerings are evolving and upgrading at quite a rapid pace, so locking into one company's offering, or another's, is really wasted money (Why pay 200/year upfront for something that looks like it will be outdated within the next month (or quarter))

> The real story is running these models at true performance max likely could go into the thousands per month per user.

A loss leader model like that failed for Uber, because there really wasn't any other constraints on competition doing the same, including under pricing to capture market share - meaning it's a race to the bottom plus a test on whose pockets were the deepest.

"discovered she has a sizable interest in All U Chart, Inc., the company that holds the IP for ICEBlock"

I'm not sure what hen's employee contract reads.

There are some limitations on US government employees engaging in political action though (Hatch act).

Perhaps hen sent a text relating to All U during work hours?

As a person who is literally doing his PhD on AML by implementing molecular subtyping, and ex-vivo drug predictions. I find this super random.

I would truly suggest our pipeline instead of random drug repurposing :)

https://celvox.co/solutions/seAMLess

edit: Btw we’re looking for ways to fund/commercialize our pipeline. You could contact us through the site if you’re interested!